Ftse Mib
34.375,92
-0,59%
DAX
18.590,89
-0,95%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
64.571,17
-0,43%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Processa Pharmaceuticals Inc (PCSA) Processa Pharmaceuticals Inc (PCSA) Notizie

PCSA

Processa Pharmaceuticals (PCSA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA
DataOraFonteTitoloSimboloCompagnia
14/12/202214:30GlobeNewswire Inc.Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A TrialNASDAQ:PCSAProcessa Pharmaceuticals Inc
08/11/202222:09Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PCSAProcessa Pharmaceuticals Inc
08/11/202222:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PCSAProcessa Pharmaceuticals Inc
08/11/202222:00GlobeNewswire Inc.Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
08/11/202214:30GlobeNewswire Inc.PCS12852 Improves Gastric Emptying in Gastroparesis PatientsNASDAQ:PCSAProcessa Pharmaceuticals Inc
02/11/202213:30GlobeNewswire Inc.Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
01/11/202213:30GlobeNewswire Inc.Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B TrialNASDAQ:PCSAProcessa Pharmaceuticals Inc
11/10/202215:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PCSAProcessa Pharmaceuticals Inc
05/10/202222:41Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
15/09/202214:30GlobeNewswire Inc.Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical ProgramsNASDAQ:PCSAProcessa Pharmaceuticals Inc
07/09/202214:30GlobeNewswire Inc.Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022NASDAQ:PCSAProcessa Pharmaceuticals Inc
16/08/202214:30GlobeNewswire Inc.Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the BoardNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/08/202213:31TipRanksAnalysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and Processa Pharmaceuticals (PCSA)NASDAQ:PCSAProcessa Pharmaceuticals Inc
12/08/202215:30GlobeNewswire Inc.Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/08/202221:00GlobeNewswire Inc.Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
04/08/202215:30GlobeNewswire Inc.Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499NASDAQ:PCSAProcessa Pharmaceuticals Inc
03/08/202222:00GlobeNewswire Inc.Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499NASDAQ:PCSAProcessa Pharmaceuticals Inc
12/07/202214:30GlobeNewswire Inc.Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022NASDAQ:PCSAProcessa Pharmaceuticals Inc
11/07/202222:44Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PCSAProcessa Pharmaceuticals Inc
31/05/202214:06Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
31/05/202214:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
12/05/202222:20GlobeNewswire Inc.Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/05/202214:30GlobeNewswire Inc.Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
20/04/202214:30GlobeNewswire Inc.Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)NASDAQ:PCSAProcessa Pharmaceuticals Inc
05/04/202214:30GlobeNewswire Inc.Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of GastroparesisNASDAQ:PCSAProcessa Pharmaceuticals Inc
30/03/202222:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PCSAProcessa Pharmaceuticals Inc
30/03/202222:00GlobeNewswire Inc.Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
24/03/202221:16Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PCSAProcessa Pharmaceuticals Inc
23/03/202213:30GlobeNewswire Inc.Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
10/03/202214:30GlobeNewswire Inc.Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA

La tua Cronologia

BIT
P23TQ1
NLBNPIT23TQ1 20240920 180
BIT
P24LV6
NLBNPIT24LV6 20250620 22
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network